BioCentury | Feb 10, 2021
Product Development

More promising preclinical data for oral COVID-19 antiviral from Ridgeback, Merck

A Nature study published Tuesday provides the most compelling preclinical evidence to date that an oral antiviral being developed by Merck and Ridgeback could be a potent outpatient and prophylactic treatment for COVID-19. The paper...
BioCentury | Oct 24, 2020
Translation in Brief

UNC Chapel Hill Angelman gene therapy rescues motor function; plus data backing planned Pacylex, Kronos clinical trials and more

AAV gene editing therapy for Angelman syndromeUniversity of North Carolina at Chapel Hill scientists have created a CRISPR gene therapy for Angelman syndrome that ameliorated motor function deficits in a mouse model of the maternally...
BioCentury | Aug 29, 2020
Product Development

COVID-19 Quick Takes: FDA expands remdesivir EUA; plus Warp Speed, Abbott, Moderna-Japan, CanSino-Canada, BeiGene-Singlomics, Sinovac, UNC, Daiichi, Laurent

Remdesivir authorized for mild patientsFDA expanded an emergency use authorization for remdesivir to include all patients hospitalized with COVID-19. The antiviral from Gilead Sciences Inc. (NASDAQ:GILD) had previously been limited to patients with blood oxygen saturation...
BioCentury | May 26, 2020

With trio of COVID deals, Merck takes a page from its Ebola strategy

Merck’s strategy to tackle COVID-19 appears to echo an approach that allowed the pharma to rapidly develop a vaccine for Ebola -- but on a much faster timeline. Merck & Co. Inc. (NYSE:MRK) said Tuesday...
BioCentury | Apr 30, 2020
Distillery Therapeutics

Heparan sulfate for prevention of acetaminophen-induced acute liver failure

DISEASE CATEGORY: Hepatic INDICATION: Liver failure Inhibiting HMGB1, a DNA-binding protein, with a polysaccharide composed of 18 heparan sulfate units could prevent acute liver failure due to acetaminophen overdose. Patients with acetaminophen-induced acute liver failure...
BioCentury | Apr 7, 2020
Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

Inovio looks to be the second company after Moderna to start a U.S. trial of a COVID-19 vaccine, kicking the study off several months ahead of its previously projected summer trial start date. Outside of...
BioCentury | Feb 28, 2020
Distillery Therapeutics

Sodium nitrite plus EDTA for bacterial infections

DISEASE CATEGORY: Infectious disease INDICATION: Pseudomonas; Gram-positive bacterial infection; Gram-negative bacterial infection Arch Biopartners’ AB569, a combination of sodium nitrite and ethylenediaminetetraacetic acid (EDTA), could treat infections by Pseudomonas aeruginosa and other bacteria. The two...
BioCentury | Feb 15, 2020
Translation in Brief

COVID-19 therapy from Emory and diagnostic from Sherlock co-founders; plus Genentech, Homology and more

Emory, UNC to test nucleoside analog against COVID-19 The Emory Institute for Drug Development and University of North Carolina at Chapel Hill are conducting preclinical studies of nucleoside analog to treat COVID-19, an Emory University...
BioCentury | Aug 15, 2019
Distillery Therapeutics

Small molecule CDK9 inhibitors for pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Small molecule CDK9 inhibitors identified through cell-based screening for destabilization of the MYC oncogene could treat pancreatic ductal adenocarcinoma (PDAC). The screen identified a CDK9 inhibitor that decreased MYC...
BioCentury | Aug 15, 2019

Deciphera’s $400M follow-on adds firepower on strength of GIST readout

Outsized investor demand continues unabated for stocks of companies with late stage clinical success stories, as evidenced by Deciphera’s ability to double the size of its follow-on to $400 million with little to no haircut...
Items per page:
1 - 10 of 180